Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Resignation of Directors
On January 30, 2023, Mr. Greg Blatt and Mr.
James Chui resigned from their positions as members of
the Board of Directors (the “Board”) of Vaxxinity,
Inc. (the “Company”) and all committees of the Board on
which they served. Mr. Blatt and Mr.
Chui’s resignations were not a result of any disagreement between Mr.
Blatt or Mr. Chui and the Company on any matter relating to the Company’s
operations, policies or practices.
Increase in Board Size; Appointment of Directors
On January 31, 2023, the Board increased the size of the Board from seven members to nine members
and appointed Katherine Eade, Landon Ogilvie, James A. Smith and Gabrielle Toledano (the “New Members”)
as members of the Board, effective February 1, 2023.
The New Members will receive customary compensation from the Company for serving as non-
employee directors, in accordance with the Company’s Non-Employee Director Compensation Policy as
described in the Company’s Definitive Proxy Statement, under the heading “Director Compensation,” filed with
the U.S. Securities and Exchange Commission (the “SEC”) on May 2, 2022 and incorporated by reference
herein. However, the New Members will not receive an initial stock option award upon joining the Board and
will instead become eligible to receive stock option awards beginning with the Company’s next annual
Effective upon the appointment of the New Members, the Board reconstituted its committees as follows:
Audit Committee: George Hornig (Chair), Peter Diamandis, Katherine Eade and James A. Smith
Compensation Committee: Gabrielle Toledano (Chair), Peter Diamandis and Landon Ogilvie
Nominating and Governance Committee: Peter Diamandis (Chair) and Gabrielle Toledano
The Board determined that each of the New Members is independent pursuant to the director
independence standards established under the Nasdaq Listing Rules and that Katherine Eade and James A.
Smith meet the additional requirements for service on the Company’s Audit Committee.
The Board designated
Landon Ogilvie as the Lead Independent Director.
There are no arrangements or understandings between the New Members and any other person pursuant
to which the New Members were appointed as directors. None of the New Members has any family
relationships with any of the Company’s directors or executive officers. There are no transactions to
Company is a party and in which any of the New Members have a material interest that are required to be
disclosed under Item 404(a) of Regulation S-K.
Item 9.01. Financial Statements and Exhibits.
Cover Page Interactive Data File (embedded within the Inline XBRL document).